somatropin + metformin + dehydroepiandrosterone

A combination product comprising **somatropin** (recombinant human growth hormone), **metformin** (an oral hypoglycemic agent, biguanide class), and **dehydroepiandrosterone** (DHEA, an adrenal steroid precursor hormone), proposed for synergistic effects in reversing or mitigating multiple aspects of human aging. This combination has been investigated for its impact on **epigenetic aging, immune cell populations (e.g., CD4/CD8 ratio), thymic function, bone marrow density, and metabolic/insulin-related side effects**. Mechanistically, somatropin acts through stimulating IGF-1 production and promoting tissue repair and regeneration; metformin improves insulin sensitivity and modulates metabolic and aging-related pathways (including AMPK activation); DHEA serves as a precursor for sex hormones and may influence immunity, inflammation, and neuroendocrine function. Together, the combination targets age-related changes in immune profile, metabolism, and tissue health, with the goal of delaying or reversing physiologic aging processes[1][3][5][7][9].

Other names

recombinant human growth hormone + metformin + DHEArhGH + metformin + dehydroepiandrosterone